Biofrontera shares rise 12.5% premarket after selling Xepi U.S. license to Pelthos for up to $10M.

Biofrontera Inc. (Nasdaq: BFRI) rose 12.5% in premarket trading following the announcement of a $10 million deal to divest its U.S. license for Xepi® (ozenoxacin) Cream to Pelthos Therapeutics. The company received $3 million at closing, with an additional $1 million tied to commercial product availability and up to $6 million in sales milestones linked to revenue thresholds. This transaction strengthens liquidity, supports profitability goals, and funds expansion of its photodynamic therapy (PDT) platform. The upfront cash infusion and potential future payments directly address cash flow concerns, aligning with the stock’s sharp premarket gain. While the company also announced Q3 2025 financial results to be released on November 12, the Xepi deal is the primary catalyst for the price movement.